- Home
- PGEN vs BME Comparison
PGEN vs BME Comparison
Compare PGEN & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGEN
- BME
- Stock Information
- Founded
- PGEN 1998
- BME 2005
- Country
- PGEN United States
- BME United States
- Employees
- PGEN N/A
- BME N/A
- Industry
- PGEN Biotechnology: Pharmaceutical Preparations
- BME Trusts Except Educational Religious and Charitable
- Sector
- PGEN Health Care
- BME Finance
- Exchange
- PGEN Nasdaq
- BME Nasdaq
- Market Cap
- PGEN 475.2M
- BME 462.3M
- IPO Year
- PGEN N/A
- BME N/A
- Fundamental
- Price
- PGEN $1.85
- BME $36.48
- Analyst Decision
- PGEN Strong Buy
- BME
- Analyst Count
- PGEN 3
- BME 0
- Target Price
- PGEN $6.00
- BME N/A
- AVG Volume (30 Days)
- PGEN 2.2M
- BME 34.0K
- Earning Date
- PGEN 08-13-2025
- BME 01-01-0001
- Dividend Yield
- PGEN N/A
- BME 6.26%
- EPS Growth
- PGEN N/A
- BME N/A
- EPS
- PGEN N/A
- BME 1.44
- Revenue
- PGEN $4,201,000.00
- BME N/A
- Revenue This Year
- PGEN $158.57
- BME N/A
- Revenue Next Year
- PGEN $1,086.91
- BME N/A
- P/E Ratio
- PGEN N/A
- BME $28.37
- Revenue Growth
- PGEN N/A
- BME N/A
- 52 Week Low
- PGEN $0.65
- BME $35.53
- 52 Week High
- PGEN $2.17
- BME $43.20
- Technical
- Relative Strength Index (RSI)
- PGEN 68.77
- BME 52.72
- Support Level
- PGEN $1.56
- BME $36.16
- Resistance Level
- PGEN $2.04
- BME $36.67
- Average True Range (ATR)
- PGEN 0.11
- BME 0.38
- MACD
- PGEN 0.04
- BME 0.04
- Stochastic Oscillator
- PGEN 70.00
- BME 66.16
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.